The role of IL‐17A in lung cancer treated with ICI is still not largely unknown, but a study showed that IL‐17A can increase the expression of PD‐L1 in colorectal cancer treated with anti‐PD‐1 therapy via p65/NRF1/miR‐15b‐5p and promotes the resistance of anti‐PD‐1 thearpy.47 This evidence concerns the gene NRF1 and colorectal cancer.